Recent Advances in Novel Lateral Flow Technologies for Detection of COVID-19

Biosensors (Basel). 2021 Aug 25;11(9):295. doi: 10.3390/bios11090295.


The development of reliable and robust diagnostic tests is one of the most efficient methods to limit the spread of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, most laboratory diagnostics for COVID-19, such as enzyme-linked immunosorbent assay (ELISA) and reverse transcriptase-polymerase chain reaction (RT-PCR), are expensive, time-consuming, and require highly trained professional operators. On the other hand, the lateral flow immunoassay (LFIA) is a simpler, cheaper device that can be operated by unskilled personnel easily. Unfortunately, the current technique has some limitations, mainly inaccuracy in detection. This review article aims to highlight recent advances in novel lateral flow technologies for detecting SARS-CoV-2 as well as innovative approaches to achieve highly sensitive and specific point-of-care testing. Lastly, we discuss future perspectives on how smartphones and Artificial Intelligence (AI) can be integrated to revolutionize disease detection as well as disease control and surveillance.

Keywords: COVID-19; SARS-CoV-2; artificial intelligence; lateral flow assay; point-of-care testing.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence
  • COVID-19 / diagnosis*
  • COVID-19 / immunology
  • COVID-19 Testing / economics
  • COVID-19 Testing / instrumentation*
  • Humans
  • Immunoassay
  • Point-of-Care Testing
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / isolation & purification*
  • Sensitivity and Specificity
  • Smartphone